BenevolentAI, a leading, clinical-stage, AI-enabled drug discovery company, is listing on Euronext Amsterdam .
The company has listed following the completion of its successful business combination with Odyssey Acquisition S.A., a special purpose acquisition company that listed on Euronext markets on 22 April 2022.
BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company with proven track-record of scientifically validated discoveries. Through the combined capabilities of its AI platform, scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The BenevolentAI Platform™ powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful commercial collaborations with leading pharmaceutical companies. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
The completion of the business combination with Odyssey, and the proceeds from the transaction, will further enable BenevolentAI to accelerate the development of its clinical pipeline and continue investing in its technology platform.
Joanna Shields, Chief Executive Officer of BenevolentAI, said: “BenevolentAI stands out in the AI-enabled drug discovery sector. Our AI platform is fully operational, scientifically validated, and supports an in-house pipeline of over 20 platform-generated drug programmes and successful commercial collaborations. Through this listing, we are well-placed to strengthen our leadership position, ensuring we can continue to accelerate investment in the development of our pipeline and technology.”